Clinical Trial Update: Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens [Phase 2]

View source ↗

Summary

Phase 2 study in pediatric patients ineligible for standard myeloablative conditioning evaluated a reduced-toxicity conditioning regimen with fludarabine and fu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: Nantes University Hospital | Conditions: Hematologic Malignancy | Phase 2 | Status: COMPLETED